Moreover, the oral administration of sildenafil increases CBF and cerebral oxygen metabolism in AD patients, suggesting that PDE5 inhibitors may serve as potential therapeutic agents for AD associated with vascular dysfunction [13]. This evidence concerns the gene PDE5A and Alzheimer disease.